Pfizer – 2023 Global Migraine ASPIRE – Competitive Research Grant Programusing Expert Review Panel- LOI

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Clinical Area: Migraine

Link to full RFP: 2023 Global Migraine ASPIRE

Specific Area of Interest: The intent of this Request for Proposal (RFP) is to support:

• Research on the therapeutic application of an oral CGRP antagonist, rimegepant, in migraine, headache, and other diseases where CGRP antagonism may be of clinical benefit
• The development of tools for clinicians and patients to improve the care of migraine patients
• Research regarding health disparities associated with migraine